Serotonin-Mediated Increase in Cytosolic [Ca++] in Platelets of Risperidone-Treated Schizophrenia Patients

Psychopharmacology Bulletin

Volumn 32, Issue 1, 1996, Pages 101-106

  Ereshefsky, Larry ^a,b   Riesenman, Cara ^a   True, Janet E ^b   Javors, Martin ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

5HT2; Calcium; Platelet; Risperidone; Serotonin

Indexed keywords

CALCIUM ION; FURA 2; HALOPERIDOL; INOSITOL TRISPHOSPHATE; RISPERIDONE; SEROTONIN; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; THROMBOCYTE RECEPTOR;

ADULT; CALCIUM CELL LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOSOL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; THROMBOCYTE;

ADULT; BLOOD PLATELETS; CALCIUM; FEMALE; HUMANS; MALE; PROGNOSIS; RISPERIDONE; SCHIZOPHRENIA; SEROTONIN;

EID: 0029938118     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Affolter, H; Erne, P; Burgisser, E; and Pletscher, A. Ca2± as messenger of 5HT2-receptor stimulation in human blood platelets. Naunyn-Schmiedebergs Arch. Pharmacol. 325:337-342, 1984.
2. American Psychiatric Association. DSM-III-R: Diagnosis and Statistical Manual of Mental Disorders. 3d ed., revised. Washington, DC: The Association, 1987.
3. Arora, RC, and Meltzer, HY. Serotonin2 receptor binding in blood platelets of schizophrenic patients. Psychiatr. Res. 47:111-119, 1993.
4. Da Prada, M; Cesura, AM; Launay, JM; and Richards, JG. Platelets as a model for neurones? Experientia 44:115-126, 1988.
5. Ereshefsky, L, and LaCombe, S. Pharmacology of risperidone. Can. J. Psychiatry 38(Suppl.):S80-S88, 1993.
6. ++ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:3440-3450, 1985.
7. Javors, MA, and Bowden, CL. The human platelet as a model for calcium metabolism in central nerve endings in the study of alcoholism. Alcohol Drug Res. 7:311-319, 1987.
8. cyt in human platelets in vitro. Cell Calcium 11:647-653, 1990.
9. Kay, SR; Fiszbein, A; and Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13:261-276, 1987.
10. ++ response in human platelets. Life Sci. 48:2405-2412, 1991.
11. Marder, SR, and Meibach, RC. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 151:825-835, 1994.
12. Pandey, SC; Sharma, RP; Janicak, PG; Marks, RC; Davis, JM; and Pandey, GN. Platelet serotonin-2 receptors in schizophrenia: Effects of illness and neuroleptic treatment. Psychiatry Res. 48:57-68, 1993.
13. Pletscher, A. Platelets as models: Use and limitations. Experientia 44:152-155, 1988.
14. Schachter, M; Geaney, DP; Grahame-Smith, DG; Cowen, PJ; and Elliott, JM. Increased platelet membrane [3H]-LSD binding in patients on chronic neuroleptic treatment. Br. J. Clin. Pharmacol. 19:453-457, 1985.
15. Schmidt, CJ; Sorensen, SM; Kehne, JH; Carr, AA; and Palfreyman, MG. The role of 5-HT2A receptors in antipsychotic activity. Life Sci. 56:2209-2222, 1995.
16. Wirz-Justice, A. Platelet research in psychiatry. Experientia 44:145-152, 1988.